Phenotypic characterization of bladder cancer.
Fradet
Y
Y
Department of Urology, Laval University, Quebec, Canada.
D000911:Antibodies, Monoclonal / Q000032:analysis*; D000951:Antigens, Neoplasm / Q000032:analysis* / Q000187:drug effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D014408:Biomarkers, Tumor / Q000032:analysis*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000473:pathology* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008207:Lymphatic Metastasis; D008297:Male; D008403:Mass Screening / Q000379:methods; D008727:Methotrexate / Q000008:administration & dosage; D008854:Microscopy, Electron; D009367:Neoplasm Staging; D010641:Phenotype; D011379:Prognosis; D012680:Sensitivity and Specificity; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000473:pathology*; D014747:Vinblastine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate